摘要
乙型肝炎病毒慢性感染呈世界性流行态势,如不及时治疗,可持续进展至肝硬化甚至肝细胞癌。近20年来,由于核苷(酸)类似物的上市及更新换代,在抑制乙肝病毒复制方面取得了质的飞跃,大多数慢性乙型肝炎(CHB)患者均可实现减轻肝细胞炎症及纤维化、改善生活质量、延长生存时间等目标。随着治疗时间的延长及治疗经验的积累,新的热点问题逐渐浮现,包括新型血清学标志物在临床的应用,CHB抗病毒治疗适应证的扩大、CHB治疗方案的制定以及长期预后的改善等,值得临床进一步关注。
Chronic hepatitis B virus infection is prevalent worldwide, and can progress to liver cirrhosis and even hepatocellular carcinoma if left untreated. Over the past 20 years, due to the approval and upgrading of nucleoside/nucleotide analogues, a qualitative leap has been made in inhibiting HBV replication. Most chronic hepatitis B(CHB) patients can achieve relief of hepatocellular inflammation, regression of hepatic fibrosis, improvement of life quality and survival time. With the extension of treatment time and the enrichment of treatment experience, new hot clinical issues gradually emerge, including the clinical application of new serum markers, the expansion of indicators for CHB antiviral treatment, the formation of CHB treatment plan and the improvement of long-term prognosis, which derserve further clinical attention.
作者
纪冬
杨永平
Ji Dong;Yang Yong-Ping(Senior Department of Hepatology,the Fifth Medical Center of Chinese PLA General Hospital,Beijing 100039,China)
出处
《解放军医学杂志》
CAS
CSCD
北大核心
2023年第2期132-137,共6页
Medical Journal of Chinese People's Liberation Army
基金
北京市自然科学基金面上项目(7222173)
国家“十三五”科技重大专项(2018ZX10725506)
解放军总医院医疗大数据与人工智能研发项目(2019MBD-024)。
关键词
乙型肝炎
慢性
诊断
治疗
预后
hepatitis B
chronic
diagnosis
treatment
outcome
